Research

My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.

Other Activities

• European Hematology Association (EHA), President 2019-2021
• President-elect 2017-2109
• EHA Governing Board, 2015-
• International workshop for NHL – Chair 2014-
• MRC Molecular and Cellular Medicine Board (MCMB), 2007-2012

Major Funding

• 2017-2022- The London Clinic, Provision of clinical research Fellows in Haematology, £1,106,617.46
• 2016-2019- Janssen Biotech Inc, Targeting PD-LI/PD-1 mediated inbhibitory signaling with BTK inhibitors, £276,416
• 2016-2019- Wellcome Trust, Understanding the rise of HIV-assoicated Hodgkin Lymphoma despite HAART; the role of immune dysregulation, £243,245
• 2015-2018- Barts Charity, Understanding the microenvironment in HIV associated Hodgkin Lymphoma, £283,221
• 2014-2019- NCI/NIH Programme Grant – CLL Research Consortium, Understanding the impact of CLL on T cell immune responses, $1,200,000

Recent Publications

Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. Aries JA, Davies JK, Auer RL et al. British Journal of Haematology (2020) (1)
https://www.ncbi.nlm.nih.gov/pubmed/32420609

Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. Waclawiczek A, Hamilton A, Rouault-Pierre K et al. J Clin Invest (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32364536

Bone marrow niches in haematological malignancies Méndez-Ferrer S, Bonnet D, Steensma DP et al. Nature Reviews Cancer (2020) 20(7) 285-298

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Edelmann J, Holzmann K, Tausch E et al. Haematologica (2020) 105(2) 1379-1390
https://www.ncbi.nlm.nih.gov/pubmed/31467127

Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. Ghazaly EA, Miraki-Moud F, Smith P et al. J Biol Chem (2020) 295(2) 5496-5508
https://www.ncbi.nlm.nih.gov/pubmed/32161116

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Tedeschi A, Greil R, Demirkan F et al. Haematologica (2020) 105(2) e164-e168
https://www.ncbi.nlm.nih.gov/pubmed/31413095

Antibody immunotherapy treatment for adults with B-acute lymphoblastic leukaemia-a real-world analysis Dexter T, Aries J, Sevillano B et al. BRITISH JOURNAL OF HAEMATOLOGY (2020) 189(11) 186-186
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000528597400262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Graft-versus-host disease: a case report of a rare but reversible cause of constrictive pericarditis. Pieri CA, Roberts N, Gribben J et al. Eur Heart J Case Rep (2020) 4(2) 1-5
https://www.ncbi.nlm.nih.gov/pubmed/32352060

Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next? Gribben JG, de Vries E, Cherny NI et al. Hemasphere (2020) 4(2) e354
https://www.ncbi.nlm.nih.gov/pubmed/32309790

Reducing Bureaucracy in Clinical Research: A Call for Action. Gribben J, Macintyre E, Sonneveld P et al. Hemasphere (2020) 4(2) e352
https://www.ncbi.nlm.nih.gov/pubmed/32309789

Team

Group Leaders in the Centre
Dr Andrejs Braun, Dr Pedro Cutillas, Dr Jeff Davies, Dr Gabriella Ficz, Professor Jude Fitzgibbon, Dr Li Jia, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench

Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove

Biography

I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.

In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.